Tangerine Borealis is a modern hybrid-indica strain bred from the genetics of G-13 and London Poundcake. The history and specific origin of this variety remain undocumented, as no definitive records exist regarding the circumstances of its breeding or the initial intentions behind the cross. Despite the lack of an established lineage narrative, the plant is a well-defined specimen that requires moderate skill to cultivate. It performs well in both indoor and outdoor environments, and growers can expect a high yield following a 65-day flowering cycle.

The sensory profile of Tangerine Borealis is dictated by a diverse array of compounds, with the specific order and dominance likely reflecting an estimated concentration of limonene, followed by myrcene, caryophyllene, linalool, beta-pinene, humulene, pinene, caryophyllene-oxide, eucalyptol, nerolidol, camphene, terpinolene, and finally ocimene. This complex chemical architecture contributes to an estimated THC content of approximately 10.1%. These compounds interact to create a nuanced aromatic and flavor experience that is characteristic of the strain’s specific terpene distribution.

In terms of functional outcomes, Tangerine Borealis promotes a state of being both relaxed and focused. These effects make the strain a candidate for individuals seeking therapeutic support for pain, stress, or assistance with sleep. As of the current record, there are no notable offspring of Tangerine Borealis, and it remains a distinct entry in the modern hybrid-indica classification.